LMU Clinical Pharmacology (@KlinPharm) header
LMU Clinical Pharmacology (@KlinPharm) profile picture

Division of Clinical Pharmacology, LMU University Hospital

Munich, Germany
Joined December 2019
Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)Photo by LMU Clinical Pharmacology (@KlinPharm)
A heartfelt thank you from KlinPharm to Prof. Stefan Endres for a lifetime of leadership 🥂@LMU_Muenchen @Harvard_Imm
1
12
617
LMU Clinical Pharmacology retweeted
Welcome, Prof. Matthias Tschöp! The internationally renowned physician and medical researcher is now President of Ludwig Maximilian University München (LMU). ✨
6
33
2,932
Another year of science, solidarity and 12 °C swims at the i-Target: Immunotargeting of Cancer annual retreat. @Baldauf_Lab @LabTheurich @buchnerlab_tum @hopfnerlab @skimhellmuth @harvardmed @LMU_Muenchen #iTarget
1
3
501
How your email finds us🏔️🥨🌻
3
274
LMU Clinical Pharmacology retweeted
#InterferonPower! Thrilled for our latest work @CellCellPress! With @dfrboehmer, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free link 👉 authors.elsevier.com/a/1leKG…
13
119
14
396
34,133
LMU Clinical Pharmacology retweeted
Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis: brnw.ch/21wUjA3
1
2
8
898
Rebalancing the Immune System to Fight Type 1 Diabetes 🔬 👉 t1p.de/n6s0g Can we go beyond symptom management in T1D treatment? A new collaborative study by #HelmholtzMunich, the German Center for Diabetes Research, and the Goethe University Frankfurt offers promising insights. Researchers investigated vidofludimus calcium, a next-generation immunomodulatory drug currently in phase 3 trials for multiple sclerosis. The drug targets DHODH, a key enzyme involved in immune cell metabolism and essential for the survival of overactive immune cells. In preclinical models, the treatment: 🔹Reduced activation of harmful T cells 🔹Increased protective regulatory T cells (Tregs) 🔹Delayed the onset of autoimmune diabetes 🗨️ “With this publication we discover for the first time that inhibiting the enzyme DHODH fosters immune-protective Tregs during islet autoimmunity and delays the progression to overt T1D in pre-clinical models.” – Prof. Carolin Daniel, senior author of the study. 💡These findings represent a significant step toward immune-based therapies for Type 1 Diabetes – shifting the focus from managing symptoms to preventing disease progression. 🔗 To the original publication: t1p.de/9c20z @DanielLabMunich @DiabResearch @goetheuni #Type1Diabetes #Immunology #DiabetesResearch #ImmuneTherapy
2
3
596
Two new doctors on the loose! Huge congratulations to Emanuele Carlini and Jan Gärtig 🥂#PhD
9
350
Great to see our new study on a vulnerable phase in HCC immunotherapy highlighted. Thank you @Erman_Akkus, and thanks to all collaborators!
1
5
447
Can't be stopped 🏃⚡️- team #KlinPharm at the B2Run in Munich's Olympiapark #B2Run2025
3
325
🥳Amazing publication from the @hornung_lab, in collab. with the @CarellThomas lab, on the innate immune system: how modified RNA tricks the immune system. Big shout-out to the two first authors, @BeroutiMarleen and Mirko Wagner! sciencedirect.com/science/ar… lmu.de/en/newsroom/news-over…
2
287
Metabolites as agents and targets for cancer immunotherapy nature.com/articles/s41573-0… This new Review discusses the role of metabolic pathways in cancer and immune cells in shaping the tumour microenvironment, and how they can be targeted to improve anticancer immune responses
4
96
3
306
20,525
LMU Clinical Pharmacology retweeted
Very excited to share our review on "Metabolites as agents and targets for cancer immunotherapy" in @NatRevDrugDisc! read it here: rdcu.be/etAMD @SpringerNature @KlinPharm
4
5
533
LMU Clinical Pharmacology retweeted
Inspired by @OliveiraMann, @BekereIndra, and Veronika Merold’s article in @MolecularCell, my latest cover art illustrates OAS2’s unique requirement for Golgi membrane localization, essential for restricting viruses! @TU_Muenchen #sciart ⌬ #research ⌬ #chemistry
I’m very excited to share our first preprint “Structural Basis for OAS2 Regulation and its Antiviral Function” from my postdoc together with Veronika Merold (Vroni) from NTase lab with @OliveiraMann biorxiv.org/content/10.1101/…
1
2
3
474
LMU Clinical Pharmacology retweeted
📢Call for Reading: *Role and Potential of Different #T Helper #Cell Subsets in Adoptive Cell Therapy* 🙌Citations: 28 👨‍🔬by David Andreu-Sanz and Sebastian Kobold #OpenAccess 🔓mdpi.com/2072-6694/15/6/1650
1
1
230
LMU Clinical Pharmacology retweeted
Structural basis for OAS2 regulation and its antiviral function dlvr.it/TLBmgD
1
6
1
39
4,636